Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival.
RDW (red cell distribution width)
glioblastoma multiforme (GBM)
hemoglobin
overall survival
prognostic factors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
12
2019
accepted:
11
03
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is known for its dismal prognosis, though its dependence on patients' readily available RBCs parameters is not fully established. In this work, 170 GBM patients, diagnosed and treated in Soroka University Medical Center (SUMC) over the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters. Besides KPS and tumor resection supplemented by oncological treatment, age under 70 (HR = 0.4, 95% CI 0.24-0.65,
Identifiants
pubmed: 32426265
doi: 10.3389/fonc.2020.00432
pmc: PMC7212453
doi:
Types de publication
Journal Article
Langues
eng
Pagination
432Informations de copyright
Copyright © 2020 Kaisman-Elbaz, Elbaz, Merkin, Dym, Noy, Atar-Vardi, Bari, Turiel, Alt, Zamed, Eskira, Lavrenkov, Kezerle, Dyomin and Melamed.
Références
Arch Intern Med. 2009 Mar 23;169(6):588-94
pubmed: 19307522
Strahlenther Onkol. 2003 Sep;179(9):615-9
pubmed: 14628127
Cell Metab. 2014 Feb 4;19(2):285-92
pubmed: 24506869
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
J Neurooncol. 2011 Aug;104(1):351-6
pubmed: 21221714
Clin Cancer Res. 2011 Aug 15;17(16):5473-80
pubmed: 21737504
J Neurosurg. 2011 Mar;114(3):604-12
pubmed: 20524825
Cancer Res. 2004 Feb 1;64(3):920-7
pubmed: 14871821
JAMA Intern Med. 2017 Apr 1;177(4):480-490
pubmed: 28241237
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2002 Jul 15;20(14):3149-55
pubmed: 12118029
J Neurooncol. 2015 Aug;124(1):87-94
pubmed: 25985958
J Neurooncol. 2013 Jun;113(2):259-66
pubmed: 23483435
Clin Transl Radiat Oncol. 2018 Apr 13;10:47-52
pubmed: 29928705
Asian Pac J Cancer Prev. 2015;16(2):411-20
pubmed: 25684464
Strahlenther Onkol. 2003 Jan;179(1):8-15
pubmed: 12540979
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
J Neurooncol. 2018 Jan;136(1):173-180
pubmed: 29076002
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
Neuro Oncol. 2012 Sep;14 Suppl 4:iv73-80
pubmed: 23095833
Int J Neurosci. 2013 Feb;123(2):133-7
pubmed: 23110493
Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1069-75
pubmed: 9869231
Med Sci Monit. 2017 Jul 01;23:3217-3223
pubmed: 28667816
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
Oncotarget. 2017 Feb 28;8(9):16027-16035
pubmed: 27926498
Onco Targets Ther. 2016 Oct 11;9:6111-6117
pubmed: 27785058
World Neurosurg. 2019 Jun;126:e1081-e1091
pubmed: 30880204
Eur J Cancer. 2015 Mar;51(4):533-42
pubmed: 25661102
Strahlenther Onkol. 2011 Dec;187(12):778-83
pubmed: 22127356
J Neurooncol. 2017 Jan;131(1):125-133
pubmed: 27644688
Neurol Res. 2018 Nov;40(11):917-922
pubmed: 30074469
Strahlenther Onkol. 2006 Feb;182(2):63-71
pubmed: 16447012
World Neurosurg. 2018 Nov;119:e710-e716
pubmed: 30092479
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
PLoS One. 2013 Jul 22;8(7):e68782
pubmed: 23894344
J Neurooncol. 2013 Aug;114(1):149-54
pubmed: 23780645
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Lab Invest. 2004 Apr;84(4):397-405
pubmed: 14990981
Cancer J. 2004 Nov-Dec;10(6):391-6
pubmed: 15701272
Oncotarget. 2017 Jul 25;8(30):50117-50123
pubmed: 28223536
J Neurooncol. 2018 Apr;137(2):279-287
pubmed: 29260361